Effects of novel HDAC inhibitors on urothelial carcinoma cells.
Aline KaletschMaria PinkerneilMichèle Janine HoffmannAnanda Ayyappan Jaguva VasudevanChenyin WangFinn K HansenConstanze WiekHelmut HanenbergChristoph G W GertzenHolger GohlkeMatthias Ulrich KassackThomas KurzWolfgang A SchulzGuenter NiegischPublished in: Clinical epigenetics (2018)
Anti-neoplastic effects of 19i on UC cells appear to be exerted by targeting class I HDACs. In fact, HDAC4 may rather impede UC growth. Our results suggest that targeting of class IIA HDACs 4/5 may not be optimal for UC therapy. Moreover, our investigation provides further evidence for cross-regulation of class IIA HDACs by class I HDACs.